
In a Phase I/II trial, CoVac-1, a peptide-based T-cell activator, induced robust SARS-CoV-2-specific T-cell responses in 86% of B-cell deficient patients. These responses surpassed those after mRNA-based vaccination, with no serious adverse events observed. CoVac-1's broad T-cell activation warrants further Phase III evaluation for safety and efficacy.
Like
Save
Share